{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
Unknown by Shizuoka College of Pharmacy
Source URL:
First approved in 2024
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ligustrazine (tetramethylpyrazine) is a bioactive ingredient extracted from the widely-used Chinese herb, Chuanxiong. It inhibits of platelet aggregation, enhances of vessel dilation, increases cerebral blood flow and possesses neuroprotective properties. The injection solution of ligustrazine has been used especially in China to treat ischemic stroke, coronary heart disease, diabetic nephropathy, and knee osteoarthritis. Ligustrazine was also evaluated in clinical as a remedy for pressure sores, as a salvage agent for patients with non-Hodgkin's lymphoma, as a treatment for bronchial asthma and vertebrobasilar insufficiency.
Status:
Possibly Marketed Outside US
Source:
Chloroquine Diphosphate by KDG Impresa LLC, Aqion
(2022)
Source URL:
First approved in 2022
Source:
Chloroquine Diphosphate by KDG Impresa LLC, Aqion
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2020
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There has been little to no interest in the biological and/or pharmacological application of lauryl phosphate.
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2020
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There has been little to no interest in the biological and/or pharmacological application of lauryl phosphate.
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 347
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Possibly Marketed Outside US
Source:
M021
(2014)
Source URL:
First approved in 2014
Source:
M021
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 356
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 355
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NCT03833089: Phase 4 Interventional Active, not recruiting Ventricular Arrhythmias and Cardiac Arrest
(2019)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
